Attached files

file filename
EX-10.2 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH MICHAEL HANDELMAN, DATED APRIL 23 - GT Biopharma, Inc.gtbp_ex102.htm
10-Q - QUARTERLY REPORT - GT Biopharma, Inc.gtbp_10-q.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.gtbp_ex321.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex311.htm
EX-10.3 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH DR. GREGORY BERK, DATED APRIL 23, - GT Biopharma, Inc.gtbp_ex103.htm
EX-10.1 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH ANTHONY CATALDO, DATED APRIL 23, - GT Biopharma, Inc.gtbp_ex101.htm
 
Exhibit 32.2
 
CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Handelman, Chief Financial Officer and Principal Accounting Officer of GT Biopharma, Inc. (the “Company”), hereby certify that, to the best of my knowledge:
 
(i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
 

 
 
 
 
 
Date: May 17, 2021
By:  
/s/ Michael Handelman
 
 
 
Name: Michael Handelman  
 
 
 
Title: Chief Financial Officer and Principal Accounting Officer